Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00934050 · ClinicalTrials.gov registry record · Phase 2
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
A Phase 2 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT00934050 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 103 participants.
The verdict
NCT00934050, a Phase 2 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
Interventions
- DRUG ELND005 (scyllo-inositol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00934050
The ClinicalTrials.gov registry entry for NCT00934050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ELND005 (scyllo-inositol) is the first listed.
NCT00934050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00934050 about?
NCT00934050 is a clinical study titled "ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease". The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
What is the current status of trial NCT00934050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2009-06. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00934050?
The interventions under investigation include: ELND005 (scyllo-inositol) (DRUG).
Who is sponsoring clinical trial NCT00934050?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.